Androgen Function in the Pathophysiology and Treatment of Male Huntington's Disease Patients

Journal of Neuroendocrinology

Volumn 24, Issue 10, 2012, Pages 1275-1283

  Ransome, M I ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Androgen; Androgen receptor; Gonadotrophic axis; Huntington's disease; Hypogonadism; Testosterone replacement therapy

Indexed keywords

ESTRADIOL; FOLLITROPIN; HUNTINGTIN; LUTEINIZING HORMONE; OREXIN; SOMATOMEDIN C; TESTOSTERONE; TRANSFORMING GROWTH FACTOR BETA1;

ALZHEIMER DISEASE; ANDROGEN INSENSITIVITY SYNDROME; ANDROGEN THERAPY; ARTICLE; BASAL GANGLION; BRAIN ATROPHY; CAG REPEAT; COGNITIVE DEFECT; DEMENTIA; DEPRESSION; DISEASE COURSE; DISEASE SEVERITY; EXERCISE; HUMAN; HUNTINGTON CHOREA; HYPOGONADISM; HYPOTHALAMUS; HYPOTHALAMUS HYPOPHYSIS GONAD SYSTEM; IMMUNOMODULATION; KENNEDY DISEASE; MALE; MALE FERTILITY; MALE INFERTILITY; NEGATIVE FEEDBACK; NEOCORTEX; NERVE CELL; NERVOUS SYSTEM DEVELOPMENT; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROTEIN AGGREGATION; PSYCHOSIS; SPERMATOGENESIS; TESTIS ATROPHY;

ANDROGENS; EXERCISE THERAPY; HUMANS; HUNTINGTON DISEASE; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; MALE; NEUROPROTECTIVE AGENTS; TESTOSTERONE; TRANSFORMING GROWTH FACTOR BETA1;

EID: 84866325964     PISSN: 09538194     EISSN: 13652826     Source Type: Journal    
DOI: 10.1111/j.1365-2826.2012.02347.x     Document Type: Article

References (92)

1. Conn MP, Freeman ME, eds. Neuroendocrinology in Physiology and Medicine. Totawa, NJ: Humana Press, 2000.
2. Conrad CD, Bimonte-Nelson HA. Impact of the hypothalamic-pituitary-adrenal/gonadal axes on trajectory of age-related cognitive decline. Prog Brain Res 2010; 182: 31-76.
3. Krause DN, Duckles SP, Gonzales RJ. Local oestrogenic/androgenic balance in the cerebral vasculature. Acta Physiol (Oxf) 2011; 203: 181-186.
4. Huntington G. On Chorea. The Medical and Surgical Reporter 1872; 26: 317-321.
5. HDCRG. (HDCRG) HsDCRG. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group. Cell 1993; 72: 971-983.
6. Corona G, Rastrelli G, Forti G, Maggi M. Update in testosterone therapy for men. J Sex Med 2011; 8: 639-654.
7. ASA. Testosterone replacement therapy for male aging: ASA position statement. J Androl 2006; 27: 133-134.
8. Carruthers M. The paradox dividing testosterone deficiency symptoms and androgen assays: a closer look at the cellular and molecular mechanisms of androgen action. J Sex Med 2008; 5: 998-1012.
9. Gil JM, Rego AC. The R6 lines of transgenic mice: a model for screening new therapies for Huntington's disease. Brain Res Rev 2009; 59: 410-431.
10. Ehrnhoefer DE, Butland SL, Pouladi MA, Hayden MR. Mouse models of Huntington disease: variations on a theme. Dis Model Mech 2009; 2: 123-129.
11. Vakiparta K, Reghu M, Andersson MR, Cao Y, Moses D, Heeger AJ. Temperature dependence of the electrical conductivity of potassium-doped polyacetylene as a function of pressure and magnetic field. Phys Rev B Condens Matter 1993; 47: 9977-9980.
12. Podolsky S, Leopold NA. Growth hormone abnormalities in Huntington's chorea: effect of L-dopa administration. J Clin Endocrinol Metab 1974; 39: 36-39.
13. Petersen A, Hult S, Kirik D. Huntington's disease - new perspectives based on neuroendocrine changes in rodent models. Neurodegener Dis 2009; 6: 154-164.
14. Kassubek J, Gaus W, Landwehrmeyer GB. Evidence for more widespread cerebral pathology in early HD: an MRI-based morphometric analysis. Neurology 2004; 62: 523-524.
15. Petersen A, Gil J, Maat-Schieman ML, Bjorkqvist M, Tanila H, Araujo IM, Smith R, Popovic N, Wierup N, Norlen P, Li JY, Roos RA, Sundler F, Mulder H, Brundin P. Orexin loss in Huntington's disease. Hum Mol Genet 2005; 14: 39-47.
16. Papalexi E, Persson A, Bjorkqvist M, Petersen A, Woodman B, Bates GP, Sundler F, Mulder H, Brundin P, Popovic N. Reduction of GnRH and infertility in the R6/2 mouse model of Huntington's disease. Eur J Neurosci 2005; 22: 1541-1546.
17. Bird ED, Chiappa SA, Fink G. Brain immunoreactive gonadotropin-releasing hormone in Huntington's chorea and in non-choreic subjects. Nature 1976; 260: 536-538.
18. Markianos M, Panas M, Kalfakis N, Vassilopoulos D. Plasma testosterone in male patients with Huntington's disease: relations to severity of illness and dementia. Ann Neurol 2005; 57: 520-525.
19. Hannan AJ, Ransome MI. Deficits in spermatogenesis but not neurogenesis are alleviated by chronic testosterone therapy in R6/1 Huntington's disease mice. J Neuroendocrinol 2012; 24: 341-356.
20. Saleh N, Moutereau S, Durr A, Krystkowiak P, Azulay JP, Tranchant C, Broussolle E, Morin F, Bachoud-Levi AC, Maison P. Neuroendocrine disturbances in Huntington's disease. PLoS ONE 2009; 4: e4962.
21. Bjorkqvist M, Petersen A, Nielsen J, Ecker D, Mulder H, Hayden MR, Landwehrmeyer B, Brundin P, Leavitt BR. Cerebrospinal fluid levels of orexin-A are not a clinically useful biomarker for Huntington disease. Clin Genet 2006; 70: 78-79.
22. Van Raamsdonk JM, Murphy Z, Selva DM, Hamidizadeh R, Pearson J, Petersen A, Bjorkqvist M, Muir C, Mackenzie IR, Hammond GL, Vogl AW, Hayden MR, Leavitt BR. Testicular degeneration in Huntington disease. Neurobiol Dis 2007; 26: 512-520.
23. Dragatsis I, Levine MS, Zeitlin S. Inactivation of Hdh in the brain and testis results in progressive neurodegeneration and sterility in mice. Nat Genet 2000; 26: 300-306.
24. Sathasivam K, Hobbs C, Turmaine M, Mangiarini L, Mahal A, Bertaux F, Wanker EE, Doherty P, Davies SW, Bates GP. Formation of polyglutamine inclusions in non-CNS tissue. Hum Mol Genet 1999; 8: 813-822.
25. McLachlan RI, O'Donnell L, Meachem SJ, Stanton PG, de Pratis K, Robertson DM. Hormonal regulation of spermatogenesis in primates and man: insights for development of the male hormonal contraceptive. J Androl 2002; 23: 149-162.
26. Galani A, Kitsiou-Tzeli S, Sofokleous C, Kanavakis E, Kalpini-Mavrou A. Androgen insensitivity syndrome: clinical features and molecular defects. Hormones (Athens) 2008; 7: 217-229.
27. Zitzmann M. The role of the CAG repeat androgen receptor polymorphism in andrology. Front Horm Res 2009; 37: 52-61.
28. Kennedy WR, Alter M, Sung JH. Progressive proximal spinal and bulbar muscular atrophy of late onset. A sex-linked recessive trait. Neurology 1968; 18: 671-680.
29. La Spada AR, Roling DB, Harding AE, Warner CL, Spiegel R, Hausmanowa-Petrusewicz I, Yee WC, Fischbeck KH. Meiotic stability and genotype-phenotype correlation of the trinucleotide repeat in X-linked spinal and bulbar muscular atrophy. Nat Genet 1992; 2: 301-304.
30. Angeli S, Shao J, Diamond MI. F-actin binding regions on the androgen receptor and huntingtin increase aggregation and alter aggregate characteristics. PLoS ONE 2010; 5: e9053.
31. Boon WC, Horne MK. Aromatase and its inhibition in behaviour, obsessive compulsive disorder and parkinsonism. Steroids 2011; 76: 816-819.
32. Bode FJ, Stephan M, Suhling H, Pabst R, Straub RH, Raber KA, Bonin M, Nguyen HP, Riess O, Bauer A, Sjoberg C, Petersen A, von Horsten S. Sex differences in a transgenic rat model of Huntington's disease: decreased 17beta-estradiol levels correlate with reduced numbers of DARPP32+ neurons in males. Hum Mol Genet 2008; 17: 2595-2609.
33. Garcia-Segura LM. Aromatase in the brain: not just for reproduction anymore. J Neuroendocrinol 2008; 20: 705-712.
34. Ooishi Y, Kawato S, Hojo Y, Hatanaka Y, Higo S, Murakami G, Komatsuzaki Y, Ogiue-Ikeda M, Kimoto T, Mukai H. Modulation of synaptic plasticity in the hippocampus by hippocampus-derived estrogen and androgen. J Steroid Biochem Mol Biol 2012; 131: 37-51.
35. Phillips W, Shannon KM, Barker RA. The current clinical management of Huntington's disease. Mov Disord 2008; 23: 1491-1504.
36. Wu FC, Tajar A, Beynon JM, Pye SR, Silman AJ, Finn JD, O'Neill TW, Bartfai G, Casanueva FF, Forti G, Giwercman A, Han TS, Kula K, Lean ME, Pendleton N, Punab M, Boonen S, Vanderschueren D, Labrie F, Huhtaniemi IT. Identification of late-onset hypogonadism in middle-aged and elderly men. N Engl J Med 2010; 363: 123-135.
37. Bates GP, Harper PS, Jones L. Huntington's Disease, 3rd edn. Oxford: Oxford University Press, 2002.
38. Galea LA, Uban KA, Epp JR, Brummelte S, Barha CK, Wilson WL, Lieblich SE, Pawluski JL. Endocrine regulation of cognition and neuroplasticity: our pursuit to unveil the complex interaction between hormones, the brain, and behaviour. Can J Exp Psychol 2008; 62: 247-260.
39. Sheffield-Moore M. Androgens and the control of skeletal muscle protein synthesis. Ann Med 2000; 32: 181-186.
40. Fanselow MS, Dong HW. Are the dorsal and ventral hippocampus functionally distinct structures? Neuron 2010; 65: 7-19.
41. MacLusky NJ, Hajszan T, Prange-Kiel J, Leranth C. Androgen modulation of hippocampal synaptic plasticity. Neuroscience 2006; 138: 957-965.
42. Kempermann G, Krebs J, Fabel K. The contribution of failing adult hippocampal neurogenesis to psychiatric disorders. Curr Opin Psychiatry 2008; 21: 290-295.
43. Pirl WF, Siegel GI, Goode MJ, Smith MR. Depression in men receiving androgen deprivation therapy for prostate cancer: a pilot study. Psychooncology 2002; 11: 518-523.
44. Timilshina N, Breunis H, Alibhai S. Impact of androgen deprivation therapy on depressive symptoms in men with nonmetastatic prostate cancer. Cancer 2012; 118: 1940-1945.
45. Zala D, Colin E, Rangone H, Liot G, Humbert S, Saudou F. Phosphorylation of mutant huntingtin at S421 restores anterograde and retrograde transport in neurons. Hum Mol Genet 2008; 17: 3837-3846.
46. Markianos M, Panas M, Kalfakis N, Vassilopoulos D. Plasma testosterone, dehydroepiandrosterone sulfate, and cortisol in female patients with Huntington's disease. Neuro Endocrinol Lett 2007; 28: 199-203.
47. Aimone JB, Deng W, Gage FH. Adult neurogenesis: integrating theories and separating functions. Trends Cogn Sci 2010; 14: 325-337.
48. Almeida OP. Vascular depression: myth or reality? Int Psychogeriatr 2008; 20: 645-652.
49. Cherrier MM. Androgens and cognitive function. J Endocrinol Invest 2005; 28: 65-75.
50. Cherrier MM, Matsumoto AM, Amory JK, Johnson M, Craft S, Peskind ER, Raskind MA. Characterization of verbal and spatial memory changes from moderate to supraphysiological increases in serum testosterone in healthy older men. Psychoneuroendocrinology 2007; 32: 72-79.
51. Seidman SN, Araujo AB, Roose SP, McKinlay JB. Testosterone level, androgen receptor polymorphism, and depressive symptoms in middle-aged men. Biol Psychiatry 2001; 50: 371-376.
52. Levine AJ, Feng Z, Mak TW, You H, Jin S. Coordination and communication between the p53 and IGF-1-AKT-TOR signal transduction pathways. Genes Dev 2006; 20: 267-275.
53. Colin E, Zala D, Liot G, Rangone H, Borrell-Pages M, Li XJ, Saudou F, Humbert S. Huntingtin phosphorylation acts as a molecular switch for anterograde/retrograde transport in neurons. EMBO J 2008; 27: 2124-2134.
54. Humbert S, Bryson EA, Cordelieres FP, Connors NC, Datta SR, Finkbeiner S, Greenberg ME, Saudou F. The IGF-1/Akt pathway is neuroprotective in Huntington's disease and involves Huntingtin phosphorylation by Akt. Dev Cell 2002; 2: 831-837.
55. Palazzolo I, Burnett BG, Young JE, Brenne PL, La Spada AR, Fischbeck KH, Howell BW, Pennuto M. Akt blocks ligand binding and protects against expanded polyglutamine androgen receptor toxicity. Hum Mol Genet 2007; 16: 1593-1603.
56. Raskin K, de Gendt K, Duittoz A, Liere P, Verhoeven G, Tronche F, Mhaouty-Kodja S. Conditional inactivation of androgen receptor gene in the nervous system: effects on male behavioral and neuroendocrine responses. J Neurosci 2009; 29: 4461-4470.
57. Culig Z, Hobisch A, Cronauer MV, Radmayr C, Trapman J, Hittmair A, Bartsch G, Klocker H. Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Cancer Res 1994; 54: 5474-5478.
58. Lin HK, Yeh S, Kang HY, Chang C. Akt suppresses androgen-induced apoptosis by phosphorylating and inhibiting androgen receptor. Proc Natl Acad Sci USA 2001; 98: 7200-7205.
59. Hobbs CJ, Plymate SR, Rosen CJ, Adler RA. Testosterone administration increases insulin-like growth factor-I levels in normal men. J Clin Endocrinol Metab 1993; 77: 776-779.
60. Muniyappa R, Sorkin JD, Veldhuis JD, Harman SM, Munzer T, Bhasin S, Blackman MR. Long-term testosterone supplementation augments overnight growth hormone secretion in healthy older men. Am J Physiol Endocrinol Metab 2007; 293: E769-E775.
61. Pandini G, Mineo R, Frasca F, Roberts CT Jr, Marcelli M, Vigneri R, Belfiore A. Androgens up-regulate the insulin-like growth factor-I receptor in prostate cancer cells. Cancer Res 2005; 65: 1849-1857.
62. Matthews R. Giving a nudge to an asteroid. Science 1992; 255: 1205.
63. Mendez P, Azcoitia I, Garcia-Segura LM. Interdependence of oestrogen and insulin-like growth factor-I in the brain: potential for analysing neuroprotective mechanisms. J Endocrinol 2005; 185: 11-17.
64. Kapadia M, Sakic B. Autoimmune and inflammatory mechanisms of CNS damage. Prog Neurobiol 2011; 95: 301-333.
65. Olsen NJ, Kovacs WJ. Gonadal steroids and immunity. Endocr Rev 1996; 17: 369-384.
66. Gold SM, Chalifoux S, Giesser BS, Voskuhl RR. Immune modulation and increased neurotrophic factor production in multiple sclerosis patients treated with testosterone. J Neuroinflammation 2008; 5: 32.
67. Buckwalter MS, Wyss-Coray T. Modelling neuroinflammatory phenotypes in vivo. J Neuroinflammation 2004; 1: 10.
68. Battaglia G, Cannella M, Riozzi B, Orobello S, Maat-Schieman ML, Aronica E, Busceti CL, Ciarmiello A, Alberti S, Amico E, Sassone J, Sipione S, Bruno V, Frati L, Nicoletti F, Squitieri F. Early defect of transforming growth factor beta1 formation in Huntington's disease. J Cell Mol Med 2011; 15: 555-571.
69. Ingman WV, Robertson SA. The essential roles of TGFB1 in reproduction. Cytokine Growth Factor Rev 2009; 20: 233-239.
70. Sapp E, Kegel KB, Aronin N, Hashikawa T, Uchiyama Y, Tohyama K, Bhide PG, Vonsattel JP, DiFiglia M. Early and progressive accumulation of reactive microglia in the Huntington disease brain. J Neuropathol Exp Neurol 2001; 60: 161-172.
71. Tai YF, Pavese N, Gerhard A, Tabrizi SJ, Barker RA, Brooks DJ, Piccini P. Microglial activation in presymptomatic Huntington's disease gene carriers. Brain 2007; 130: 1759-1766.
72. Sugama S, Takenouchi T, Cho BP, Joh TH, Hashimoto M, Kitani H. Possible roles of microglial cells for neurotoxicity in clinical neurodegenerative diseases and experimental animal models. Inflamm Allergy Drug Targets 2009; 8: 277-284.
73. Garcia-Ovejero D, Veiga S, Garcia-Segura LM, Doncarlos LL. Glial expression of estrogen and androgen receptors after rat brain injury. J Comp Neurol 2002; 450: 256-271.
74. Iliev AI, Stringaris AK, Nau R, Neumann H. Neuronal injury mediated via stimulation of microglial toll-like receptor-9 (TLR9). FASEB J 2004; 18: 412-414.
75. Rettew JA, Huet-Hudson YM, Marriott I. Testosterone reduces macrophage expression in the mouse of toll-like receptor 4, a trigger for inflammation and innate immunity. Biol Reprod 2008; 78: 432-437.
76. Razmara A, Krause DN, Duckles SP. Testosterone augments endotoxin-mediated cerebrovascular inflammation in male rats. Am J Physiol Heart Circ Physiol 2005; 289: H1843-H1850.
77. Ahlskog JE, Geda YE, Graff-Radford NR, Petersen RC. Physical exercise as a preventive or disease-modifying treatment of dementia and brain aging. Mayo Clin Proc 2011; 86: 876-884.
78. Walsh NP, Gleeson M, Shephard RJ, Woods JA, Bishop NC, Fleshner M, Green C, Pedersen BK, Hoffman-Goetz L, Rogers CJ, Northoff H, Abbasi A, Simon P. Position statement. Part one: immune function and exercise. Exerc Immunol Rev 2011; 17: 6-63.
79. Hackney AC. Exercise as a stressor to the human neuroendocrine system. Medicina (Kaunas) 2006; 42: 788-797.
80. Cotman CW, Berchtold NC, Christie LA. Exercise builds brain health: key roles of growth factor cascades and inflammation. Trends Neurosci 2007; 30: 464-472.
81. van Dellen A, Cordery PM, Spires TL, Blakemore C, Hannan AJ. Wheel running from a juvenile age delays onset of specific motor deficits but does not alter protein aggregate density in a mouse model of Huntington's disease. BMC Neurosci 2008; 9: 34.
82. Potter M, Yuan C, Ottenritter C, Mughal M, van Praag H. Exercise is not beneficial and may accelerate symptom onset in a mouse model of Huntington's disease. PLoS Curr 2010; 2: RRN1201.
83. Carro E, Nunez A, Busiguina S, Torres-Aleman I. Circulating insulin-like growth factor I mediates effects of exercise on the brain. J Neurosci 2000; 20: 2926-2933.
84. Hasani-Ranjbar S, Soleymani Far E, Heshmat R, Rajabi H, Kosari H. Time course responses of serum GH, insulin, IGF-1, IGFBP1, and IGFBP3 concentrations after heavy resistance exercise in trained and untrained men. Endocrine 2012; 41: 144-151.
85. Hering S, Jost C, Schulz H, Hellmich B, Schatz H, Pfeiffer H. Circulating transforming growth factor beta1 (TGFbeta1) is elevated by extensive exercise. Eur J Appl Physiol 2002; 86: 406-410.
86. Rojas Vega S, Knicker A, Hollmann W, Bloch W, Struder HK. Effect of resistance exercise on serum levels of growth factors in humans. Horm Metab Res 2010; 42: 982-986.
87. Gibney J, Healy ML, Sonksen PH. The growth hormone/insulin-like growth factor-I axis in exercise and sport. Endocr Rev 2007; 28: 603-624.
88. Quinn L, Busse M, Khalil H, Richardson S, Rosser A, Morris H. Client and therapist views on exercise programmes for early-mid stage Parkinson's disease and Huntington's disease. Disabil Rehabil 2010; 32: 917-928.
89. Aziz NA, Pijl H, Frolich M, van der Graaf AW, Roelfsema F, Roos RA. Increased hypothalamic-pituitary-adrenal axis activity in Huntington's disease. J Clin Endocrinol Metab 2009; 94: 1223-1228.
90. Altschuler EL. Strenuous, intensive, long-term exercise does not prevent or delay the onset of Huntington's disease. Med Hypotheses 2006; 67: 1429-1430.
91. Sah DW, Aronin N. Oligonucleotide therapeutic approaches for Huntington disease. J Clin Invest 2011; 121: 500-507.
92. Myers RH. Huntington's disease genetics. NeuroRx 2004; 1: 255-262.